- $116.47m
- $28.47m
- $18.11m
- 28
- 19
- 71
- 33
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.65 | ||
| Price to Tang. Book | 1.65 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.43 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -28.15% | ||
| Return on Equity | -24.66% | ||
| Operating Margin | -130.97% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.48 | 0.7 | 10.18 | 9.29 | 18.11 | n/a | n/a | 64.33% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 1st, 2011
- Public Since
- February 9th, 2021
- No. of Employees
- 174
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 55,145,839
- Address
- 4F, Building C14, No. 218, SUZHOU, 215123
- Web
- https://www.adagene.com/
- Phone
- +86 51287773632
- Auditors
- PricewaterhouseCoopers Zhong Tian LLP
Upcoming Events for ADAG
Similar to ADAG
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adicet Bio
NASDAQ Global Market
FAQ
What is the Adagene share price?
As of Today at 19:00 UTC, shares in Adagene are trading at $2.64. This share price information is delayed by 15 minutes.
How has the Adagene share price performed this year?
Shares in Adagene last closed at $2.64 and the price had moved by +78.38% over the past 365 days. In terms of relative price strength the Adagene share price has outperformed the S&P500 Index by +48.44% over the past year.
What are the analyst and broker recommendations for Adagene?
The overall consensus recommendation for Adagene is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Adagene dividend yield?
Adagene does not currently pay a dividend.
Does Adagene pay a dividend?
Adagene does not currently pay a dividend.
When does Adagene next pay dividends?
Adagene does not currently pay a dividend.
How do I buy Adagene shares?
To buy shares in Adagene you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Adagene?
As of the previous close price of $2.64, shares in Adagene had a market capitalisation of $116.47m.
Where are Adagene shares listed?
Here are the trading details for Adagene:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ADAG
What kind of share is Adagene?
Based on an overall assessment of its quality, value and momentum Adagene is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Adagene share price forecast for 2024?
The analyst consensus target price for shares in Adagene is $12.00. That is 354.55% above the last closing price of $2.64.
Analysts covering Adagene currently have a consensus Earnings Per Share (EPS) forecast of -$0.90 for the next financial year.
What is the trend in the Adagene share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adagene. Over the past six months, its share price has outperformed the S&P500 Index by +60.09%.
As of the last closing price of $2.64, shares in Adagene were trading +28.48% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Adagene PE Ratio?
The Adagene PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.64.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Adagene?
We do not have data on Adagene's directors